1215787-31-7

Basic information

• Product Name: 6-BroMo-4-chloropyrido[2,...
• Synonyms: 6-BroMo-4-chloropyrido[2,...
• CAS NO: 1215787-31-7
• Molecular Formula: C₇H₃BrClN₃
• Molecular Weight: 244.47582
• Product Categories: Heterocycle-Pyrimidine series
• Mol File: 1215787-31-7.mol
• Article Data: 9

Chemical Properties

• Melting Point: 152-154 °C
• Boiling Point: 334.0±37.0 °C(Predicted)
• Appearance: /
• Density: 1.861±0.06 g/cm3(Predicted)
• Storage Temp.: Inert atmosphere,Store in freezer, under -20°C
• PKA: -1.41±0.30(Predicted)
• CAS DataBase Reference: 6-BroMo-4-chloropyrido[2,...(CAS DataBase Reference)
• NIST Chemistry Reference: 6-BroMo-4-chloropyrido[2,...(1215787-31-7)
• EPA Substance Registry System: 6-BroMo-4-chloropyrido[2,...(1215787-31-7)

Safety Data

• Hazardous Substances Data: 1215787-31-7(Hazardous Substances Data)

Usage

General Description

6-Bromo-4-chloropyrido[2,3-d]pyrimidine is a chemical compound with the molecular formula C7H3BrClN3. It is a heterocyclic compound containing a pyrimidine ring with bromine and chlorine substituents. 6-BroMo-4-chloropyrido[2,... is a potential building block for the synthesis of various pharmaceuticals and agrochemicals. It has been used as a starting material in the development of new drugs and as a key intermediate in the production of crop protection products. 6-BroMo-4-chloropyrido[2,... is mainly synthesized through organic reactions involving the condensation of appropriate starting materials under carefully controlled conditions. Its unique structure and reactivity make it a valuable compound for the discovery and development of novel biologically active substances.

Upstream product

• 155690-79-2 6-bromo-pyrido[2,3-d]pyrimidin-4-ol 
• 52833-94-0 2-amino-5-bromonicotinicacid 
• 155690-79-2 6-bromo-3H,4H-pyrido[2,3-d]pyrimidin-4-one 
• 5345-47-1 2-aminopyridin-3-carboxylic acid 
• 1121633-45-1 6-bromopyrido[2,3-d]pyrimidin-4-amine 
• 13362-26-0 2-aminopyridine-3-carboxylic acid ethyl ester 
• 433226-06-3 2-amino-5-bromonicotinic acid ethyl ester 

Downstream Products

• 1121633-45-1 6-bromopyrido[2,3-d]pyrimidin-4-amine 

Relevant articles and documents

Design, synthesis, anti-tumor activity, and molecular modeling of quinazoline and pyrido[2,3-d]pyrimidine derivatives targeting epidermal growth factor receptor

Three series of novel quinazoline and pyrido[2,3-d]pyrimidine derivatives were designed, synthesized and evaluated for their ability to inhibit EGFR tyrosine kinase and a panel of five human cancer cell lines (MCF-7, A549, BT-474, SK-BR-3, and MDA-MB-231)

Pyrido[2,3-d]pyrimidine compound as well as preparation method and application thereof

The present invention discloses a pyrido[2,3-d]pyrimidine compound represented by a general formula I or a pharmaceutically acceptable salt thereof. The general formula I is shown as the specification, wherein R1 is selected from one of an alkylamine group of C1-C6, an alicyclic amine group of C1-C6, a heterocyclic amine group of C1-C6, and an aromatic amine group of C6-C8, and X represents a hydrogen atom or a halogen atom. According to the invention, in-vitro cell activity tests prove that the compound provided by the invention has antitumor activity and can be used for preparing medicines for treating and/or preventing various cancers caused by BRaf kinase mutation, such as melanoma, thyroid cancer, breast cancer, liver cancer, kidney cancer, colorectal cancer, pancreatic cancer, ovarian cancer, etc.

Synthesis, Crystal Structure, and DFT Study of a New Derivative of Pyrido[2,3-d]pyrimidine

Abstract: N-{4-[(6-bromopyrido[2,3-d]pyrimidin-4-yl)oxy]phenyl}morpholine-4-carboxamide has been synthesized as a derivative of pyrido[2,3-d]pyrimidine that demonstrates antitumor, antibacterial, anti-inflammatory, and antimicrobial activities. Synthesis of the target compound based on 2-aminonicotinic acid as the starting material has included its esterification, bromination, cyclization, and substitution reactions. Structure of the product is confirmed by 1H and 13C NMR, FT-IR, and single-crystal X-ray diffraction (XRD). The optimized structure, electrostatic potential and frontier molecular orbitals (FMO) of the compound have been approached by DFT calculations. The compound demonstrates antiproliferative activity on A375 cells.